AHRQ (Agency for Healthcare Research and Quality) casts doubt on TMR/PMR (transmyocardial revascularisation)/(percutaneous myocardial revascularisation) for angina
This article was originally published in Clinica
A new Medicare-commissioned technology assessment is highly critical of transmyocardial revascularisation (TMR) and percutaneous myocardial revascularisation (PMR) as a way of treating the crushing pain of angina. The report by the federal Agency for Healthcare Research and Quality (AHRQ) was released ahead of an upcoming Medicare Coverage Advisory Committee meeting on TMR and PMR and could induce Medicare to curtail its coverage of the two technologies.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.